Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2000
10/19/2000WO2000061221A1 Method of providing cosmetic/medical therapy
10/19/2000WO2000061204A1 Three-dimensional stromal tissue
10/19/2000WO2000061189A2 Water-soluble compositions of bioactive lipophilic compounds
10/19/2000WO2000061188A1 Sodium channel blocker compositions and the use thereof
10/19/2000WO2000061184A2 Dry formulation for transcutaneous immunization
10/19/2000WO2000061180A2 Products and methods for treating ptp lar related diseases
10/19/2000WO2000061173A2 Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy
10/19/2000WO2000061171A2 Uses of mammalian ox2 protein and related reagents
10/19/2000WO2000061167A2 TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
10/19/2000WO2000061164A1 Modulation of excitable tissue function by peripherally administered erythropoietin
10/19/2000WO2000061162A1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
10/19/2000WO2000061152A1 Management of pain after joint surgery
10/19/2000WO2000061150A1 Antisense modulation of fas mediated signaling
10/19/2000WO2000061146A1 Camptothecin analogs and methods of preparation thereof
10/19/2000WO2000061145A1 Methods of inducing cancer cell death and tumor regression
10/19/2000WO2000061141A2 Methods and compositions for enhancing delivery of therapeutic agents to tissues
10/19/2000WO2000061132A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000WO2000061130A1 Compounds useful in reducing the level of insulin like growth factor-1 (igf-1) in blood
10/19/2000WO2000061112A2 Solubilized pharmaceutical composition for parenteral administration
10/19/2000WO2000060932A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1
10/19/2000WO2000041505A3 Anthranilic acid derivatives
10/19/2000WO2000035484A3 Methods and compositions for decreasing allergic reactions to surface allergens
10/19/2000WO2000034308A3 Protein transduction system and methods of use thereof
10/19/2000WO2000032778A3 Methods and compositions for inhibiting neoplastic cell growth
10/19/2000WO2000032769A3 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides
10/19/2000WO2000032208A3 Isolated material having an anti-organotrophic effect
10/19/2000WO2000024437A3 Textured and porous silicone rubber
10/19/2000WO2000024405A9 Compounds and their therapeutic use with diabetic complications
10/19/2000WO2000013702A9 Use of an angiogenic factor for the treatment of microvascular angiopathies
10/19/2000WO2000012507A8 Pyrrolobenzodiazepines
10/19/2000WO2000009070A3 Inhibition of pathogenic processes related to tissue trauma
10/19/2000DE19917505A1 Treating cytokine-mediated diseases, e.g. asthma, allergy, eczema, rheumatoid arthritis or transplant rejection, using new or known maduraphthalazine derivatives
10/19/2000DE19917233A1 New stable, soluble crystalline sodium salt of 5-chloro-2-methoxy-N-(2-phenylethyl)-benzamide derivative, is an ATP-sensitive potassium channel blocker useful e.g. for treating cardiac arrhythmia or ischemia
10/19/2000DE19916837A1 New di- or tetrahydro-benzoazulene derivatives, are integrin inhibitors useful e.g. for treating thrombosis, coronary heart disease, arteriosclerosis, tumors, osteoporosis or rheumatoid arthritis
10/19/2000DE19916719A1 Neue ECE-Inhibitoren, ihre Herstellung und Verwendung New ECE inhibitors, their preparation and use
10/19/2000DE19915465A1 Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten Using a Caspase inhibitor for the inhibition of proliferation of cells and using one or more caspase inhibitor / s for the treatment of diseases based on lymphocyte hyperproliferation or for suppression of an immune response by lymphocytes
10/19/2000DE19915057A1 Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung Monoclonal antibodies to human protein Mcm3, processes for their preparation and their use
10/19/2000CA2696826A1 Process for preparing inhibitors of nucleoside metabolism
10/19/2000CA2383940A1 Modulation of excitable tissue function by peripherally administered erythropoietin
10/19/2000CA2382628A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000CA2371223A1 49 human secreted proteins
10/19/2000CA2370767A1 49 human secreted proteins
10/19/2000CA2370489A1 49 human secreted proteins
10/19/2000CA2370425A1 Pharmaceutical compounds
10/19/2000CA2370406A1 Pharmaceutical compounds
10/19/2000CA2370267A1 Prodrugs of thrombin inhibitors
10/19/2000CA2370237A1 Methods for the diagnosis and treatment of metastatic prostate tumors
10/19/2000CA2370189A1 48 human secreted proteins
10/19/2000CA2370131A1 62 human secreted proteins
10/19/2000CA2370112A1 Uncoupling proteins
10/19/2000CA2370039A1 Apoptosis-associated gene
10/19/2000CA2370000A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
10/19/2000CA2369981A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
10/19/2000CA2369971A1 Aryl or heteroaryl fused imidazole derivatives, their pharmaceutical compositions and agents, and uses thereof
10/19/2000CA2369666A1 N-substituted-n'-substituted urea derivatives and the use thereof as tnf-.alpha production inhibitory agents
10/19/2000CA2369654A1 N-substituted-n'-substituted urea derivatives and pharmaceutical compositions containing said derivatives
10/19/2000CA2369619A1 Caspase inhibitors and the use thereof
10/19/2000CA2369454A1 Uses of mammalian ox2 protein and related reagents
10/19/2000CA2369420A1 Treatment of myeloma bone disease with proteasomal and nf-kb activity inhibitors
10/19/2000CA2369381A1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
10/19/2000CA2369301A1 Management of pain after joint surgery
10/19/2000CA2369263A1 Methods and compositions for enhancing delivery of therapeutic agents to tissues
10/19/2000CA2369156A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1
10/19/2000CA2369103A1 Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
10/19/2000CA2369084A1 Compounds useful in reducing the level of insulin like growth factor-1 (igf-1) in blood
10/19/2000CA2368830A1 Prodrugs of thrombin inhibitors
10/19/2000CA2368655A1 Dry formulation for transcutaneous immunization
10/19/2000CA2368648A1 Estrogen receptors and bone
10/19/2000CA2366671A1 Methods and reagents for determining enzyme substrate specificity, and uses related thereto
10/19/2000CA2365945A1 Products and methods for treating ptp lar related diseases
10/19/2000CA2365918A1 49 human secreted proteins
10/19/2000CA2365910A1 Human proteins and polynucleotides encoding them
10/19/2000CA2365908A1 Reagents and methods for identifying and modulating expression of genes regulated by p21
10/19/2000CA2365905A1 48 human secreted proteins
10/19/2000CA2365522A1 48 human secreted proteins
10/19/2000CA2364675A1 Methods of inducing cancer cell death and tumor regression
10/19/2000CA2364577A1 Regulation of repressor genes using nucleic acid molecules
10/19/2000CA2364536A1 Fragments of virus protein 2 or 3 of polyoma virus, as vehicules for active substances
10/19/2000CA2356128A1 Method of providing cosmetic/medical therapy
10/19/2000CA2306039A1 Hcv combination therapy
10/18/2000EP1044987A2 Gapped 2'-modified oligonucleotides
10/18/2000EP1044970A1 Aminotriazole compounds, process for their preparation and pharmaceutical compositions containing them
10/18/2000EP1044967A2 2-Pyridinylguanidine urokinase inhibitors
10/18/2000EP1044267A2 Novel nucleic acid and polypeptide with homology to the tnf-receptors
10/18/2000EP1044263A2 CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
10/18/2000EP1044218A1 Nucleic acids encoding transferrin receptor-like proteins and products related thereto
10/18/2000EP1044217A2 Sag: sensitive to apoptosis gene
10/18/2000EP1044215A1 Anti-inflammatory phenylalanine derivatives
10/18/2000EP1044212A1 Human fk506 binding proteins
10/18/2000EP1044206A1 Prodrugs of naaladase inhibitors
10/18/2000EP1044203A1 3'-epimeric k-252a derivatives
10/18/2000EP1044201A1 3-substituted adenines via2-thioxanthines
10/18/2000EP1044189A1 Aryl fused azapolycyclic compounds
10/18/2000EP1044186A1 Substituted 2-benzylamino-2-phenyl-acetamide compounds
10/18/2000EP1044020A2 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products
10/18/2000EP1044015A1 Formulations for amylin agonist peptides
10/18/2000EP1044004A1 A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors
10/18/2000EP1044001A1 Integrin receptor antagonists
10/18/2000EP1043999A1 Novel substituted pyridine compounds useful as modulators of acetylcholine receptors
10/18/2000EP1043998A1 USE OF PYRAZOLO 3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
1 ... 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 ... 1564